The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
AACR 2023 | Ruxolitinib in combination with abemaciclib for patients with primary or post-PV/ET myelofibrosis
Jan Philipp Bewersdorf, MD, Memorial Sloan Kettering Cancer Center, New York City, NY, discusses a Phase I dose-escalation study evaluating the combination of ruxolitinib and abemaciclib in patients with primary or post-polycythemia vera (PV)/essential thrombocythemia (ET) myelofibrosis (MF). Dr Bewersdorf explains the rationale behind combining these two agents and further highlights the importance of exploring novel treatment approaches for patients who discontinue treatment with ruxolitinib. Two patients have been enrolled in this trial and no dose-limiting toxicities have been observed. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
